Advance JV Group Ltd is offering 2,500,000 ordinary shares at $2.00 per share, seeking gross proceeds of US$5,000,000.
Vik Khadilkar no longer holds that portfolio-management role from the same date. The change removes references to Khadilkar in the fund’s prospectus materials and adds Modiano’s profile.
Macquarie Energy Transition Infrastructure Fund, L.P. sold unregistered limited partnership units for approximately $2,389,000 ($2.389 million) on August 3, 2026, excluding interests issued through its distribution reinvestment plan. Units went to third-party investors.
Nuveen California Select Tax Free Income Portfolio has identified Doshi Parth as an insider and reported his initial stake in the portfolio.
ETUARYTM FY26 total revenue guidance is $100.5M-$111M, according to an updated corporate presentation from GYRE Therapeutics, Inc. (NASDAQ: GYRE) made available on September 1, 2026. The presentation positions the company’s China commercial operations alongside a development strategy spanning protein degraders and degrader antibody conjugates.
A new insider position has been recorded for Lewis Sheri at Merit Medical Systems (NASDAQ: MMSI) Inc. where he serves as EVP of Global Operations.
The disclosure identifies PULSE BIOSCIENCES, INC (NASDAQ: PLSE). As the organisation associated with the position and names Teplitsky as its chief operating officer.
Advisers Investment Trust’s Independent Franchise Partners US Equity Fund has removed Michael Allison from its portfolio-manager roster after his retirement from Independent Franchise Partners LLP.
The development gives investors tracking NAZ a named insider connection without attaching a numerical value to the position.
Adicet Bio, Inc. (NASDAQ: ACET) completed the final patient visit for a planned analysis of prulacabtagene leucel, known as prula-cel, in systemic lupus erythematosus patients with or without lupus nephritis. Topline results are expected in September 2026, followed by an investor webcast covering the …